Serum levels of IFN-γ and IL-4 in hospitalised COVID-19 patients – evidence of reduced cytokine storm in discharged patients

Ładowanie...
Obrazek miniatury
Data
2023-12
Autorzy
Arinola, Ganiyu Olatunbosun
Onifade, Abdulfattah Adekunle
Adigun, Kehinde
Oshingbesan, Mosunmade Babatunde
Tytuł czasopisma
ISSN
Tytuł tomu
Wydawnictwo
Publishing Office of the University of Rzeszow
Abstrakt
Introduction and aim. Coronavirus disease 2019 is characterised by cytokine storm and it was managed with repurposed drugs, however the effect of this treatment on cytokine storm is unknown. The aim of the study was to investigate the effect of repurposed management on serum Th1 pro-inflammation cytokine (IFN-γ) and Th2 anti-inflammation cytokine (IL-4) in COVID-19 patients. Material and methods. The levels of IFN-γ and IL-4 were determined in sera from 45 COVID-19 patients at admission followed-up till discharge after repurposed treatment using ELISA. The mean levels and proportions above normal reference ranges of IFN-γ and IL-4 were compared in COVID-19 at admission and discharge. Results. The mean values of IFN-γ and IL-4 were significantly higher in COVID-19 patients at admission compared with discharged COVID-19 patients whereas IFN-γ:IL-4 ratio was significantly higher in discharged COVID-19 patients compared with admitted COVID-19 patients. Significantly higher proportion of COVID-19 patients at discharge had IFN-γ within the normal reference ranges compared with COVID-19 patients at admission whereas the proportions of COVID-19 patients at discharge and COVID-19 patients at admission having IL-4 within the normal reference ranges were the same. Conclusion. Cytokine storm was evidenced in COVID-19 patients at admission and repurposed treatment suppressed pro-inflammation cytokine (IFN-γ) in most discharged COVID-19 patients.
Opis
Ethical approval was granted by the Institutional Ethical Committee with approval number UI/EC/20/0283.
Słowa kluczowe
cytokine storm , re-purposed treatment , SARS-CoV-2
Cytowanie
European Journal of Clinical and Experimental Medicine T. 21, z. 4 (2023), s. 750–755